Table 1.
The characteristics of the patients treated with bortezomib-based therapy and healthy donors. Data are presented as frequency and percentage (%) unless otherwise specified.
| Characteristics | Total | Primary refractory | Early relapse | Sensitive | Healthy donors |
|---|---|---|---|---|---|
| Number of patients | 71 | 13 | 28 | 30 | 30 |
| Gender N (%) |
M: 42 (59.1) F: 29 (39.9) |
M: 8 (61.5) F: 5 (38.5) |
M: 17 (60.7) F: 11 (39.3) |
M: 17 (56.7) F: 13 (43.3) |
M: 18 (60.0) F: 12 (40.0) |
| Age at initial bortezomib treatment Mean + SD (range) |
64.6 ± 11.2 (39-91) |
69.1 ± 9.7 (46-81) |
65.6 ± 12.0 (39-91) |
61.6 ± 10.6 (42-82) |
52.1 ± 8.8 (37-70) |
| Bortezomib regimen: | |||||
| VCD | 58 (81.7) | 10 (76.9) | 21 (75.0) | 27 (90.0) | — |
| VMP | 6 (8.5) | 2 (15.4) | 4 (14.3) | 0 | — |
| VTD | 3 (4.2) | 0 | 1 (3.6) | 2 (6.7) | — |
| VD | 3 (4.2) | 1 (7.7) | 2 (7.1) | 0 | — |
| IsaVRd | 1 (1.4) | 0 | 0 | 1 (3.3) | — |
| Time from diagnosis to bortezomib treatment initiation—days—median (IQR) | 16.5 (4-45) | 96.0 (22-1356) | 13.0 (4-39.5) | 11.0 (3-35) | — |
| Paraprotein: N (%) | |||||
| IgG | 42 (59.2) | 10 (76.9) | 16 (57.1) | 16 (53.3) | — |
| IgA | 14 (19.7) | 2 (15.4) | 9 (3.2) | 3 (10.0) | — |
| LCD | 15 (21.1) | 1 (7.7) | 3 (10.7) | 11 (36.7) | — |
| Bone involvement at diagnosis | 39 (54.9) | 7 (53.8) | 17 (60.7) | 16 (53.3) | — |
| Calcium > 2.75 mmol/l at diagnosis | 11 (15.5) | 0 | 8 (28.6) | 3 (10.0) | — |
| HB < 10 g/dl at diagnosis | 28 (39.4) | 6 (46.2) | 8 (28.6) | 14 (46.7) | — |
| Creatinine > 2 mg/dl at diagnosis | 11 (15.5) | 0 | 4 (14.3) | 7 (23.3) | — |
| International Staging System (ISS) at diagnosis | I—18 (25.4) | I—4 (30.8) | I—7 (25.0) | I—7 (23.3) | — |
| II—17 (23.9) | II—3 (23.1) | II—7 (25.0) | II—7 (23.3) | — | |
| III—34 (47.9) | III—6 (46.2) | III—13 (46.4) | III—15 (50.0) | — | |
| CRP mg/l—median (IQR) | 3.0 (1.0-7.4) | 2.2 (1.1-5.9) | 2.4 (1.3-6.3) | 4.1 (1.0-7.3) | — |
| Beta-2-microglobuline increased (>3 mg/l) | 49 (69.0) | 9 (69.2) | 21 (75.0) | 19 (63.3) | — |
| LDH > 240 U/l | 9 (12.7) | 3 (23.1) | 2 (7.1) | 4 (13.3) | — |
| Cytogenetics—(%) | N = 38 | N = 3 | N = 18 | N = 17 | — |
| t(11; 14) | 2.6 | 0 | 5.6 | 0 | — |
| t(4; 14) | 15.8 | 0 | 22.2 | 11.8 | — |
| t(14; 16) | 0 | 0 | 0 | 0 | — |
| t(14; 20) | 0 | 0 | 0 | 0 | — |
| del(17p) | 13.2 | 0 | 16.7 | 11.8 | — |
| amp(1q) | 55.3 | 33.3 | 61.1 | 52.9 | — |
| del(13q) | 23.7 | 0 | 16.7 | 35.3 | — |
Abbreviations: LCD—light chain disease; VCD—bortezomib, cyclophosphamide, and dexamethasone; VD—bortezomib and dexamethasone; VMP—bortezomib, melphalan, and prednisone; VTD—bortezomib, thalidomide, and dexamethasone; IsaVRd—isatuximab, lenalidomide, bortezomib, and dexamethasone; IQR—interquartile range.